Overview

A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.

Phase:

Phase 2

Details

Lead Sponsor:

Sheba Medical Center

Treatments:

Lenvatinib
Pembrolizumab